Professor Michael Thompson obtained his undergraduate degree from the University of Wales, UK and his PhD in analytical chemistry from McMaster University. Following a period as Science Research Council PDF at Swansea University he was appointed Lecturer in Instrumental Analysis at Loughborough University. He then moved to the University of Toronto where he is now Professor of Bioanalytical Chemistry. He has held a number of distinguished research posts including the Leverhulme Fellowship at the University of Durham and the Science Foundation Ireland E.T.S Walton Research Fellowship at the Tyndall National Institute, Cork City. He is recognized internationally for his pioneering work over many years in the area of research into new biosensor technologies and the surface chemistry of biochemical and biological entities. He has made major contributions to the label-free detection of immunochemical and nucleic acid interactions and surface behavior of cells using ultra high frequency acoustic wave physics. Thompson has served on the Editorial Boards of a number of major international journals including Analytical Chemistry and The Analyst and is currently Editor-in-Chief of the monograph series “Detection Science” for the Royal Society of Chemistry, UK. He has been awarded many prestigious international prizes for his research including The Robert Boyle Gold Medal of the Royal Society of Chemistry and the E.W.R. Steacie Award of the Chemical Society of Canada. He was made a Fellow of the Royal Society of Canada in 1999.
Terry Ann Else obtained her PhD at the University of Nevada, Las Vegas in 2002. She is an Associate Professor at Touro University Nevada teaching medical microbiology/immunology to medical and graduate level students since 2004. She is board certified as a Clinical Laboratory Scientist. Her research interests include bacteriophage therapy research studying the pathogens, Streptococcus pneumoniae and Neisseria gonorrhoeae, in collaboration with Associate Professor Karen Duus, PhD also at Touro University Nevada. Terry Ann Else has been active in the American Society for Microbiology and served as regional planning coordinator for local ASM branches in the southwestern US and Hawaii.
John J.S. Cadwell received his degree in pharmacology from the University of Miami in 1981. He spent additional time studying at the University of Nottingham and the National Institute of Medical Research at Mill Hill, outside of London. He served in various capacities in the biomedical research fields until 2000 when he was founder of FiberCell Systems Inc. a company specializing in the research and supply of hollow fiber bioreactors. He has over 10 publications in the field and three patents relating to hollow fiber systems and is considered a world expert in the field.
Ananda M. Chakrabarty, Ph.D., is a Distinguished University Professor at the University of Illinois College of Medicine at Chicago. While working at the Research & Development Center at General Electric Company in Schenectady, New York, he was awarded the ‘Scientist of the Year’ award in 1975 by Industrial Research Organization of the United States. This work led to the development of a genetically-manipulated microorganism that was the subject matter of a landmark decision from the Supreme Court of the United States that genetically engineered life forms are patentable. Dr. Chakrabarty has served as a consultant with the United Nations and was the founding member of a UNIDO Committee that proposed the establishment of the International Centre for Genetic Engineering & Biotechnology (ICGEB) based in Trieste, Italy, New Delhi, India, and Cape Town, South Africa. Dr. Chakrabarty has been a member of the Panel of Scientific Advisors, later called Council of Scientific Advisors, of ICGEB since its very inception. Dr. Chakrabarty has also been a member of the International Advisory Board of Chulabhorn Research Institute in Thailand, which is headed by the Princess Chulabhorn of Thailand, and a member of the Scientific Advisory Committee of the Department of Biotechnology (DBT) under the Ministry of Science & Technology, Govt. of India
Dr. Debabrata Biswas is an Assistant Professor of Food Safety in the Department of Animal and Avian Sciences, and Center for Food safety and Security Systems at the University of Maryland-College Park, MD. Dr. Biswas is a bacteriologist and has committed to develop crosscutting research programs in foodborne bacterial infection control and food safety area. His research focuses on developing alternatives to sub-therapeutic (growth promoting) and therapeutic (animal disease control) and mitigate the emerging issue of antibiotic resistance bacterial pathogens in farm animal production system. His research also target to define the colonization mechanism of foodborne zoonotic bacterial pathogens their in animal reservoirs and the mechanism by which pathogens become resistance against antimicrobial components. He also investigates the role of natural products in control of foodborne bacterial colonization in animals and mechanism of antimicrobial activity of these components.
CEO of Nanorx INC has a Ph.D. in Organic Chemistry from Oregon State University(1979) and an M.S in Chemistry(1972) from I.I.T Mumbai, India.He has worked on drug discovery for over 25 years at Columbia University, Max-Planck Institute, Germany, Ciba-Geigy (now Novartis) and Boehringer Ingelheim. He has over 15 US and International patents and another 15 pending patent applications
Akira Kaji is a professor of microbiology, School of Medicine, University of Pennsylvania. He contributed to the deciphering of genetic code by his discovery of the fact that the complex of poly-U with ribosome binds specifically tRNA specific for phenylalanine. He also discovered RRF.
John F. Kokai-Kun, PhD is Vice President of Non-clinical Affairs for Synthetic Biologics, Inc. (Rockville, MD). He received his BS in Biochemistry from Juniata College in Huntingdon, PA and his PhD in Microbiology from the University of Pittsburgh, School of Medicine. He served as a post-doctoral researcher at the Uniformed Services University of the Health Sciences in Bethesda, MD. Dr. Kokai-Kun has 20 years of experience in the drug development industry and has held positions with several biotechnology and pharmaceutical companies where his research and development efforts have focused primarily on anti-bacterial drugs and vaccines. He is also an Adjunct Assistant Professor of Microbiology and Immunology at the Uniformed Services University.
Saeed El-Ashram is an Associate Professor of Parasitology, Faculty of Science, Kafr El-Sheikh University, Kafr El-Sheikh, Egypt. He is the holder of several issued and pending patents in the field of Parasitology. He is also the Inventor of “Compositions and methods of enhancing immune responses to Eimeria” (United States Patent 8956849).
Dr. Saeed El-Ashram scientific interests include parasitology, Immunology, Veterinary Medicine. His recent publications include Gel Mapping to Differentiate between Sporozoites of Two Immunologically Distinct Strains of Eimeria maxima (Strains M6 and Guelph), ) Interferon-Gamma Release Assay,Exploring Early and Late Toxoplasma gondii Strain RH Infection by Two-Dimensional Immunoblots of Chicken Immunoglobulin G and M and Mycoplasma gallisepticum MGA_0676 is a membrane-associated cytotoxic nuclease with a staphylococcal nuclease region essential for nuclear.
Glenn Tillotson has over 30 years pharmaceutical experience in pre-clinical and clinical research, commercialization, medical affairs, scientific communications including publication planning strategic drug development, life cycle management and global launch programs. Dr Tillotson has been instrumental in the development and launch of ciprofloxacin, moxifloxacin, gemifloxacin, fidaxomicin and several other agents. Dr Tillotson is SVP of Medical Affairs where he is preparing for the launch of solithromycin for community acquired bacterial pneumonia. Glenn has held several key committee positions at the American College of Chest Physicians, he is on the Scientific Steering Committee for the GTCBio Annual Summit on Anti-infective Partnering. Currently Dr Tillotson has published >170 peer-reviewed manuscripts, presented >270 scientific posters and is on several journal Editorial Advisory Boards including the Lancet Infectious Disease, eBioMedicine, Expert Reviews in Anti-infective Therapy and F1000.